Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.92)
# 3,048
Out of 4,876 analysts
99
Total ratings
35.8%
Success rate
-8.75%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.75 | +82.15% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.40 | +108.33% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $1.73 | +246.82% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $20.78 | +116.55% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $52.94 | +58.67% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $110.15 | -0.14% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $43.77 | -13.18% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $13.50 | +11.11% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $52.70 | +0.57% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $3.13 | +219.49% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $37.79 | +85.23% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.73 | +15.61% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.90 | +902.64% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.56 | +241.73% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.45 | +512.24% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.35 | +965.34% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $30.51 | +17.99% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.36 | +528.93% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.38 | +59.91% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $11.78 | +197.11% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.64 | +603.23% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.33 | +2,164.15% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.06 | +1,795.73% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $2.54 | +293.70% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.20 | +246.15% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.38 | +1,715.54% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.30 | -46.97% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $22.03 | -9.21% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.96 | +56.05% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.72 | +2,193.58% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.80 | +503.45% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.51 | +3,874.83% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.86 | +529.37% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.75
Upside: +82.15%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.40
Upside: +108.33%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $1.73
Upside: +246.82%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $20.78
Upside: +116.55%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $52.94
Upside: +58.67%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $110.15
Upside: -0.14%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $43.77
Upside: -13.18%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.50
Upside: +11.11%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $52.70
Upside: +0.57%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.13
Upside: +219.49%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $37.79
Upside: +85.23%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.73
Upside: +15.61%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.90
Upside: +902.64%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.56
Upside: +241.73%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.45
Upside: +512.24%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.35
Upside: +965.34%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $30.51
Upside: +17.99%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.36
Upside: +528.93%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.38
Upside: +59.91%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $11.78
Upside: +197.11%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.64
Upside: +603.23%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.33
Upside: +2,164.15%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.06
Upside: +1,795.73%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $2.54
Upside: +293.70%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $5.20
Upside: +246.15%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.38
Upside: +1,715.54%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.30
Upside: -46.97%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $22.03
Upside: -9.21%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.96
Upside: +56.05%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.72
Upside: +2,193.58%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $5.80
Upside: +503.45%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.51
Upside: +3,874.83%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.86
Upside: +529.37%